Compare Definium Therapeutics Inc. Common Shares (DFTX) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs MasterCard Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while MasterCard Inc trades at $574.59 (market cap $499.38B). The key difference: MasterCard Inc is far larger — about 106× Definium Therapeutics Inc. Common Shares's market cap, and MasterCard Inc pays a 0.61% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and MasterCard Inc for 134 Days on average.
| DFTX | MA | |
|---|---|---|
Market Cap | $4.71B | $499.38B |
Volume | 1,966,636 | 1,862,680 |
Sector | Health | Financials |
52-Week High | $48.45 | $599.86 |
52-Week Low | $10.68 | $471.55 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $3.67B | $512.41B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mastercard (MA) trades at $574.76, up 1.44% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 46.3% net margins and 241.5% ROE, supported by growing institutional interest. Recent news highlights Mastercard's AI and digital payment initiatives, while analyst consensus remains strongly bullish with an $666.67 price target.
Outlook remains positive given earnings momentum and strategic positioning in digital payments, though competition from emerging payment technologies presents a key risk. The stock offers growth potential but requires monitoring of payment industry disruption and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
